Compare Inovio Pharmaceuticals Inc (INO) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PPG Industries, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while PPG Industries, Inc. trades at $115.63 (market cap $25.79B). The key difference: PPG Industries, Inc. is far larger — about 288.9× Inovio Pharmaceuticals Inc's market cap, and PPG Industries, Inc. pays a 2.56% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PPG | |
|---|---|---|
Market Cap | $89.27M | $25.79B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $131.56 |
52-Week Low | $1.05 | $94.34 |
Enterprise Value | $60.28M | $31.90B |
Dividend Yield | — | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
PPG Industries trades at $115.71, down 1.41% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 results with $15.88B revenue and $1.58B net income, and recently raised its dividend to $0.74 per share, reflecting confidence in cash flow. Analyst consensus is bullish with a $132.20 price target, though Q2 2026 earnings due July 28 are key for near-term direction.
The outlook is positive given solid profitability and dividend growth, but risks include economic sensitivity and debt levels. Upside potential exists if Q2 earnings beat expectations, while a miss could pressure the stock. The current valuation at a P/E of 16.58 appears reasonable relative to historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
